| Title |
Novel Targets for Inflammatory Bowel Disease Therapeutics
|
|---|---|
| Published in |
Current Gastroenterology Reports, January 2013
|
| DOI | 10.1007/s11894-012-0311-3 |
| Pubmed ID | |
| Authors |
Mark Löwenberg, Geert D’Haens |
| Abstract |
In recent years, many new agents have been evaluated for the treatment of inflammatory bowel disease. In this paper, we critically review recently published literature about these novel therapies, which have been the result of extensive research identifying molecular targets. Of the various biologicals and small molecules that have recently been tested in clinical trials, several demonstrated clinical efficacy with a tolerable safety profile. We discuss a number of them with specific focus on vedolizumab, a monoclonal antibody directed against the alpha4beta7 integrin on lymphocytes, ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, and tofacitinib, a small molecule targeting Janus-activated kinase. Most likely, these three agents will find their way to the market and offer significant therapeutic alternatives for the management of Crohn's disease and/or ulcerative colitis. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Australia | 1 | <1% |
| Unknown | 105 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 27 | 25% |
| Other | 16 | 15% |
| Student > Ph. D. Student | 11 | 10% |
| Student > Postgraduate | 8 | 7% |
| Student > Bachelor | 8 | 7% |
| Other | 21 | 19% |
| Unknown | 17 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 39% |
| Agricultural and Biological Sciences | 18 | 17% |
| Immunology and Microbiology | 5 | 5% |
| Computer Science | 4 | 4% |
| Unspecified | 4 | 4% |
| Other | 13 | 12% |
| Unknown | 22 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2013.
All research outputs
#20,723,696
of 25,457,297 outputs
Outputs from Current Gastroenterology Reports
#3
of 3 outputs
Outputs of similar age
#230,337
of 290,947 outputs
Outputs of similar age from Current Gastroenterology Reports
#1
of 1 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.9. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,947 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them